EUCTR2013-000322-66-SE进行中（未招募）1 期
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant efficacy andsafety Outcomes with an eveRolimus-based regiMen (TRANSFORM) - Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,040
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent obtained.
- •2. Subject randomized within 24 hr of completion of transplant surgery.
- •3. Recipient of a kidney with a cold ischemia time < 30 hours.
- •4. Recipient of a primary (or secondary, if first graft is not lost due to immunological reasons) renal transplant from a deceased heart beating, living unrelated, living related non-human leukocyte antigen identical or an expanded criteria donor.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2040
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •1. Subject unable to tolerate oral medication at time of randomization.
- •2. Use of other investigational drugs at the time of enrollment
- •3. History of hypersensitivity to any of the study drugs or similar chemical classes.
- •4. multi-organ transplant recipient
- •5. Recipient of ABO incompatible allograft or complement-dependent lymphocytotoxic (CDC) crossmatch positive transplant
- •6. high immunological risk by assessment of anti-donor reactivity e.g. high PRA, presence of pre-existing DSA
- •7. HIV positive
- •8. HBsAg and/or a HCV positive with evidence of elevated LFTs (ALT/AST levels = 2.5 times ULN)
- •9. Recipient of a kidney from a donor who tests positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV)
- •10. BMI greater than 35
- •11. severe systemic infections
- •12. Subject requiring systemic anticoagulation
- •13. History of malignancy
- •14. severe restrictive or obstructive pulmonary disorders
- •15. severe hypercholesterolemia or hypertriglyceridemia
- •16. white blood cell (WBC) count = 2,000 /mm3 or with platelet count = 50,000 /mm3.
- •17. Pregnant or nursing (lactating) women
- •18. Women of child-bearing potential
研究者
相似试验
进行中（未招募）
1 期
This study CRAD001A2433 is designed to evaluate the impact of concentration-controlled everolimus with reduced exposure CNI, comparedto mycophenolic acid (MPA) with standard exposure CNI, with respect to efficacy and safety in de novo renal transplant recipients.Adult kidney transplant recipients.MedDRA version: 20.0Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2013-000322-66-SIovartis Pharma Services AG2,040
进行中（未招募）
1 期
Efficacy and safety of concentration-controlled everolimus with reduced Calcineurin Inhibitor (CNI) exposure, compared to Mycophenylate (MPA) and stand CNI exposure in de novo kidney transplant.Adult kidney transplant recipients.MedDRA version: 16.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857EUCTR2013-000322-66-GRovartis Pharma Services AG2,040
进行中（未招募）
1 期
This study CRAD001A2433 is designed to evaluate the impact of concentration-controlled everolimus with reduced exposure CNI, compared to mycophenolic acid (MPA) with standard exposure CNI, with respect to efficacy and safety in de novo renal transplant recipients.Adult kidney transplant recipients.MedDRA version: 19.0Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2013-000322-66-DEovartis Pharma Services AG2,040
进行中（未招募）
1 期
Study evaluating the effect of treatment with everolimus in combination with reduced calcineurin inhibitor compared to a standard treatment in kidney transplant recipients.EUCTR2013-000322-66-HRovartis Pharma Services AG2,037
招募中
4 期
To evaluate the graft function of everolimus and reduced Calcineurin Inhibitor versus mycophenolic acid sodium and standard Calcineurin Inhibitor in adult renal transplant recipients.CTRI/2014/07/004772ovartis Healthcare Private Limited1,972